2561 — Visen Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- HK$4.99bn
- HK$4.78bn
Annual income statement for Visen Pharmaceuticals, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS |
| Standards: | HKAS | HKAS | HKAS |
| Status: | Final | Final | Final |
| Revenue | |||
| Total Revenue | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||
| Research And Development | |||
| Unusual Expense / Income | |||
| Other Operating Expenses | |||
| Total Operating Expenses | 288 | 249 | 182 |
| Operating Profit | -288 | -249 | -182 |
| Total Net Non Operating Interest Income / Expense | |||
| Net Income Before Taxes | -289 | -250 | -182 |
| Provision for Income Taxes | |||
| Net Income After Taxes | -289 | -250 | -182 |
| Net Income Before Extraordinary Items | |||
| Net Income | -289 | -250 | -182 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||
| Income Available to Common Shareholders Including Extraordinary Items | |||
| Diluted Net Income | -289 | -250 | -182 |
| Diluted Weighted Average Shares | |||
| Basic EPS Including Extraordinary Items | |||
| Diluted EPS Including Extraordinary Items | |||
| Diluted EPS Excluding Extraordinary Items | |||
| Normalised Income Before Taxes | |||
| Normalised Income After Taxes | |||
| Normalised Income Available to Common Shareholders | |||
| Diluted Normalised EPS | -2.43 | -2.07 | -1.47 |